Justin M. Holub

Justin M. Holub

Auto-generated profile, based on publicly available information

Justin M. Holub

Department of Chemistry and Biochemistry, Ohio University , Athens, OH 45701

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
CXChang Xu
Chang Xu
WZWei Zhang
Wei Zhang
RWRuixia Wang
Ruixia Wang
STShuzhi Tan
Shuzhi Tan
JHJustin M. Holub
Justin M. Holub
BTBo Tang
Bo Tang

16 June 2003 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
MEMichael Evans
Michael Evans
DSDaniel C. Smith
Daniel C. Smith
JHJustin M. Holub
Justin M. Holub
AAAnthony Argenti
Anthony Argenti
MHMafoloe Hoff
Mafoloe Hoff
IHIris H. Hall
Iris H. Hall

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RBReetobrata Basu
Reetobrata Basu
KNKhairun Nahar
Khairun Nahar
PKPrateek Kulkarni
Prateek Kulkarni
OKOlivia Kerekes
Olivia Kerekes
MSMaya Sattler
Maya Sattler
JKJohn J. Kopchick
John J. Kopchick
Excess circulating human growth hormone (hGH) in vivo is linked to metabolic and growth disorders such as cancer, diabetes and acromegaly. Consequently, there is considerable interest in developing antagonists of hGH action. Here, we present the design, synthesis and characterization of a 16-residue peptide (S1H) that inhibits hGH-mediated STAT5 phosphorylation (pSTAT5) in cultured cells. S1H was designed as a direct sequence mimetic of the site 1 mini-helix (residues 36-51) of wild-type hGH and acts by inhibiting the interaction of hGH with the human growth hormone receptor (hGHR). In vitro studies indicated that S1H is stable in human serum and can adopt an α-helix in solution. Our results also show that S1H mitigates phosphorylation of STAT5 in cells co-treated with hGH, reducing intracellular pSTAT5 levels to those observed in untreated controls. Furthermore, S1H was found to attenuate the activity of the hGHR and the human prolactin receptor (hPRLR), suggesting that this peptide acts as an antagonist of both lactogenic and somatotrophic hGH actions. Finally, we used alanine scanning to determine how discrete amino acids within the S1H sequence contribute to its structural organization and biological activity. We observed a strong correlation between helical propensity and inhibitory effect, indicating that S1H-mediated antagonism of the hGHR is largely dependent on the ability for S1H to adopt an α-helix. Taken together, these results show that S1H not only acts as a novel peptide-based antagonist of the hGHR but can also be applied as a chemical tool to study the molecular nature of hGH-hGHR interactions.

5 November 2015 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
MHM. Margaret Harris
M. Margaret Harris
ZCZachary Coon
Zachary Coon
NANajah Alqaeisoom
Najah Alqaeisoom
BSBrian Swords
Brian Swords
JHJustin M. Holub
Justin M. Holub
BH3 domain mimetics based on the small protein scyllatoxin (ScTx) were designed to target the anti-apoptotic protein Bcl2 in vitro. Intrinsically disordered ScTx variants were found to bind Bcl2 with nanomolar affinity, indicating that an induced fit binding mechanism is required for favorable BH3 : Bcl2 interaction.

10 August 2017 in Drug Development Research
Verified
Journal Article
Closed access
PDF file
JHJustin M. Holub
Justin M. Holub

22 March 2017 in Journal of Peptide Science
Verified
Journal Article
Closed access
PDF file
DADanushka Arachchige
Danushka Arachchige
MHM. Margaret Harris
M. Margaret Harris
ZCZachary Coon
Zachary Coon
JCJacob Carlsen
Jacob Carlsen
JHJustin M. Holub
Justin M. Holub